Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status

Author： Chang Gee-Chen   Chen Kun-Chieh   Yang Tsung-Ying   Yin Ming-Chang   Lin Ching-Pei   Kuo Benjamin Ing-Tiau   Hsu Jeng-Yuan  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.23, Iss.1, 2005-01, pp. : 73-77

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Spotlight on Gefitinib in Non-Small-Cell Lung Cancer

By Frampton James E.   Easthope Stephanie E.  

American Journal of PharmacoGenomics, Vol. 5, Iss. 2, 2005-01 ,pp. : 133-136

Adis International

Access to resources Recommend Favorite

Gefitinib: A Review of its Use in the Management of Advanced Non-Small-Cell Lung Cancer

By James E. Frampton   Stephanie E. Easthope  

Drugs, Vol. 64, Iss. 21, 2004-01 ,pp. : 2475-2492

Adis International

Access to resources Recommend Favorite

Increased von Willebrand factor over decreased ADAMTS‐13 activity is associated with poor prognosis in patients with advanced non‐small‐cell lung cancer

By  

Journal Of Clinical Laboratory Analysis (Electronic), Vol. 32, Iss. 1, 2018-01 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gefitinib in non-small cell lung cancer

By Tamura Kenji   Fukuoka Masahiro  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 6, 2005-06 ,pp. : 985-993

Informa Healthcare

Access to resources Recommend Favorite

Bortezomib with or without docetaxel has modest activity for refractory or recurrent advanced non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1565, 2006-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite